{
    "nct_id": "NCT03422393",
    "official_title": "A Phase 1 Clinical Trial to Evaluate Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.",
    "inclusion_criteria": "* Clinical and phenotypic verification of B cell CLL or SLL and measurable disease.\n* Prior therapy: Patients must have been receiving single agent ibrutinib therapy at the time of disease progression. Patient may have received other therapy in combination with ibrutinib earlier in their treatment course.\n* Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study.\n* Adequate hematologic, hepatic and renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known CNS lymphoma or leukemia\n* History of Richter's or prolymphocytic transformation.\n* Primary ibrutinib resistance\n* Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP)\n* History of major surgery within 4 weeks prior to first dose on this study.\n* History of prior malignancy, with the exception of adequately treated non-melanoma skin cancer, malignancies treated with curative intent and with no evidence of active disease for more than 3 years, or adequately treated cervical carcinoma in situ without current evidence of disease.\n* Active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first dose.\n* Active hepatitis B or C infection.\n* Known history of infection with human immunodeficiency virus (HIV).\n* Unable to swallow capsules or disease significantly affecting gastrointestinal function.\n* History of stroke or intracranial hemorrhage within 6 months of first dose.\n* Requires anticoagulation with warfarin or other Vitamin K antagonists.\n* Requires treatment with a strong cytochrome P(CYP)450 3A inhibitor.\n* Pregnant or breast-feeding women\n* Current infection requiring parenteral antibiotics.\n* Active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification.\n* Patients who require immediate cytoreduction due to high risk of tumor lysis syndrome (ie, absolute lymphocyte count greater than 100k/uL).",
    "miscellaneous_criteria": ""
}